| This week's sponsor is Roquette. | |  | Roquette - The Biological Choice
Sole custody of our supply chain ensures a safe, secure and reliable supply of quality raw materials and excipients. Trust Roquette for all your biopharma needs. Learn more. |
Featured Story Tuesday, April 18, 2017  As the battle between Swiss major Novartis and biotech rival Kite Pharma heats up to be the first to market a CAR-T cancer med, the Big Pharma has been handed its second FDA "breakthrough" tag for its eagerly awaited JULIET trial.
| This week's sponsor is Sensors Expo & Conference 2017. | |  | |
Top Stories Tuesday, April 18, 2017 Allergan has wasted little time in testing out its new fatty liver candidate that it got in the potentially $1.7 billion buyout of Tobira last year as it pens a new deal to wed cenicriviroc to Novartis’ lead FXR agonist in a midstage test. Tuesday, April 18, 2017 Circassia has pulled the plug on its allergy programs after falling short in another study. The string of failures continued with the publication of subpar data from a house dust mite allergy phase 2b, forcing the company to pivot away from the assets that drove it to a £200 million ($251 million) IPO in 2014. Tuesday, April 18, 2017 Motif Bio has posted data from a phase 3 trial of its antibiotic candidate iclaprim. The drug held its own against established antibiotic vancomycin, setting Motif Bio on a path it sees leading to a filing for FDA approval in the first half of next year. Tuesday, April 18, 2017 Ionis Pharmaceuticals has enlisted the help of Suzhou Ribo Life Science to help it bring three of its RNA-based drugs to the Chinese market. Monday, April 17, 2017 Bristol-Myers Squibb and Denmark’s Nordic Bioscience inked a deal to develop biomarker technology to diagnose and monitor fibrotic diseases such as nonalcoholic steatohepatitis (NASH). Monday, April 17, 2017 Celgene has reached its first licensing agreement in the Asia-Pacific region with China-based young biotech Antengene, which will be helped by CRO Tigermed with clinical development. Tuesday, April 18, 2017 Cobra Biologics will inject $19 million into facilities located in the U.K. and Sweden to help the CDMO meet increased demand from gene and immunotherapy companies, the company said. | This week's sponsor is J.P. Morgan Private Bank. | |  | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | Cancer biotech and biopharma favorite Zymeworks has set terms for its $65 million initial public offering. Renaissance Capital article Belgium-based inflammatory biotech Galapagos saw its public offering total $338 million. Statement (PDF) Struggling CAR-T biotech Juno Therapeutics has taken on former Genentech exec Sunil Agarwal as president of its research and development unit. Release | |
|
Resources Sponsored By: LMK Clinical Research Consulting Training is a vital component of workplace efficiency especially when it comes to one of the most important deliverables of a clinical trial – the Trial Master File (TMF). Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! Presented By: Enterprise Florida As life sciences companies decide to implement shared services, a major concern is real estate costs for a facility. Download this Whitepaper to learn why Florida is gaining traction as a prime location for shared services. | 
